Search

Displaying results 6591 - 6600 of 7181 in total
  1. Drug

    Tanespimycin

    go.drugbank.com/drugs/DB05134
    Investigational

    Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90).

  2. Drug

    AM336

    go.drugbank.com/drugs/DB06563
    Experimental

    Leconotide (development codes CNSB004 and AM336) is an omega-conotoxin peptide known for its analgesic properties, which work by blocking neuronal voltage-sensitive calcium channels.

    Categories: Calcium Channels, N-Type
  3. Drug

    EHC18

    go.drugbank.com/drugs/DB05114
    Experimental

    EHC18 is an immune regulation medicine. It is a broad spectrum of specific HCV proteins.

  4. Drug

    Zilebesiran

    go.drugbank.com/drugs/DB18929
    Investigational

    Zilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care

  5. Drug

    EGT-101

    go.drugbank.com/drugs/DB17645
    Experimental

    Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type A.[L45919]

  6. Drug

    RESP301

    go.drugbank.com/drugs/DB16497
    Investigational

    RESP301 was under investigation in clinical trials for various conditions. It was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults with rifampicin-susceptible...

  7. Drug

    Adomiparin

    go.drugbank.com/drugs/DB06005
    Investigational

  8. Drug

    Bleomycin A6

    go.drugbank.com/drugs/DB12992
    Investigational

    It was shown that besides the antitumor effect, Bleomycin A6 had the ability to alter the tumor microenvironment and could contribute toward lung cancer relapse and metastasis on long-term treatment.

  9. Drug

    Fulzerasib

    go.drugbank.com/drugs/DB21609
    Investigational

    Fulzerasib is under investigation in clinical trial NCT06936644 (A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-

  10. Drug

    RPI-MN

    go.drugbank.com/drugs/DB17957
    Experimental

    [A260132] Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.[L47107]